Meaghanelizabeth Berry
Durham, NCNPI 1457960171
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.6% of the total across 230 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by AbbVie at 27.5% of the total. 2025 is the largest year on record at $2,528, more than ten times the $188 reported in 2022.
Across 230 payments — averaging $22.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$592
- Vanda Pharmaceuticals Inc.$558
- Teva Pharmaceuticals USA, Inc.$421
- Alkermes, Inc.$418
- Otsuka America Pharmaceutical, Inc.$401
- plus $1K from 13 others
What the payments were for
- Food & beverage$4,97396%
- Education$2304%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 81 | $1,430 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 20 | $592 |
| Vanda Pharmaceuticals Inc. | 14 | $558 |
| Teva Pharmaceuticals USA, Inc. | 13 | $421 |
| Alkermes, Inc. | 22 | $418 |
| Otsuka America Pharmaceutical, Inc. | 13 | $401 |
| Supernus Pharmaceuticals, Inc. | 24 | $330 |
| Neurocrine Biosciences, Inc. | 6 | $264 |
| Corium, LLC | 10 | $181 |
| E.r. Squibb & Sons, L.L.C. | 6 | $175 |
| Lundbeck LLC | 7 | $120 |
| Biogen | 2 | $101 |
| Neos Therapeutics, LP | 4 | $71 |
| Ironshore Pharmaceuticals Inc. | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $34 |
| Tris Pharma Inc | 1 | $22 |
| OWP Pharmaceuticals, Inc. | 1 | $20 |
| Collegium Pharmaceutical, Inc. | 1 | $17 |
| Noven Therapeutics, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$446
- Fanapt$343
- CAPLYTA$244
- ABILIFY MAINTENA$122
- ABILIFY ASIMTUFII$122
- INGREZZA$122
- REXULTI$115
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydroxyzine Hcl | 20 | $250 |
| Atomoxetine Hcl | 11 | $187 |
| Fluoxetine Hcl | 13 | $37 |
| Alprazolam | 15 | $30 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.